Chronic lymphocytic leukaemia (CLL) is a heterogeneous disease with a variable clinical course. Deletions of the long arm of chromosome 11 (11q-) and especially the short arm of chromosome 17 (17p-) are the strongest independent prognostic factors associated with an adverse outcome.
1 17p-corresponds to allelic loss of the tumour suppressor gene, p53, whereas 11q-implies loss of the ataxia telangiectasia (ATM) gene, an upstream mediator in the p53 signalling pathway, and both are associated with dysfunction of the p53 tumour suppressor pathway. 2 These chromosomal abnormalities may play an important role in relapse on therapy, as the prevalence of 17p-and 11q-increases from 5-15% at diagnosis to over 50% during relapse. 3 Currently, fluorescence in situ hybridisation (FISH) is a widely used technique to detect chromosomal anomalies in cancer samples. Although recent studies show that deletions of one p53 or ATM alleles are frequently accompanied by mutation of the other allele, the exact overlap between the patient populations defined by such deletions and p53 dysfunction remains poorly defined. It would therefore be clinically relevant to test the activity of the p53 pathway in a functional assay, in addition to FISH analysis.
Measuring p53 and/or p21 protein levels by western blot (WB) following ionising radiation (IR) is an accepted semi-quantitative method to detect p53 (dys)function in tumour samples. 2, 4 Alternative techniques have also been described, such as flowcytometric staining of the cell-surface receptor CD95 4 or intracellular staining of p53 and p21 5 after IR, and Functional Analysis of Separated Alleles in Yeast (FASAY). 6 Earlier, we have evaluated the apoptosis gene profile of CLL samples after fludarabine incubation through reverse transcriptase-multiplex ligation-dependent probe amplification (RT-MLPA) analysis, and observed that induction of expression of the p53 responsive gene, Puma strictly relied on functional p53. 7 In the current report, the potential of RT-MLPA to establish p53 function was evaluated further by including the p53-responsive cell cycle inhibitor, p21. The multiplex RT-MLPA procedure is able to quantify expression of genes in small RNA samples, and was applied as described earlier 7 in 31 bloodderived CLL samples (purity 490% CD5 þ /CD19 þ ) treated with or without IR (5 Gy) and cultured for 16 h at 37 1C. We compared the results with two other read-outs of p53 function: p53 and p21 protein expression (WB analysis) and induction of expression of surface-bound CD95 as detected by flowcytometry. Patients 1-23 were randomly included from our cohort and tested for p53 function by WB analysis for p53, p21 and Puma protein induction on IR (Figure 1a) , whereas patients 24-31 were included based on clinical refractoriness to standard chemotherapy and/or FISH analysis that showed 17p-or 11q-status. In total, nine patients had detectable 17p deletions and eight had 11q deletions as assessed by FISH (see Table 1 ).
Of the 34 apoptosis-related genes in the modified RT-MLPA probe set applied here, three are acknowledged targets of p53: Puma, p21 and Bax. In most samples, these genes were induced on IR (Figure 1b and Table 1 ). We considered first those samples without abnormalities involving 17p and 11q, as well as clear p53 and p21 protein induction on western blot. Fifteen CLL samples met these criteria, and their average gene induction measured by RT-MLPA minus 2 Â SD was taken as cut-off value for normal p53 function. When all three cut-off values for Puma, p21 and Bax were met, a sample was considered functional for p53.
Next, p53 function in the patients with documented 11q-and 17p-were analyzed. In seven out of eight patients with 11q-(range 11-95%), no p53 dysfunction could be detected by WB, RT-MLPA or FACS method. Of note, patient 28 (75% 11q-) was a borderline case with p21 below and Bax and Puma above the RT-MLPA cut-off (repeated twice), and no CD95 induction by FACS, who showed rapid disease progression and chemotherapy resistance. Plotting the percentage of 11q-as detected by FISH versus the Puma or p21 induction by MLPA of these eight samples did not show a significant correlation ( Figure 1c ). This analysis seems to be in line with recent data indicating that in the majority of patients with 11q-, the remaining ATM allele is intact and as a consequence p53 function is normal. 8 In five chemotherapy-refractory patients with 17p-cells in the range of 53-94%, p53 dysfunction was apparent according to RT-MLPA analysis. In contrast, samples of three patients with a lower percentage of 17p-(15-39%) showed a normal p53 function by all three methods. This could also be seen by plotting the percentage of 17p-cells against fold induction of Puma and p21 on IR measured by RT-MLPA ( Figure 1c) . A significant linear correlation was observed in this limited set of nine patients, but it also seemed to be clear that beyond 450% 17p-cells, there is a sharp decline in functional response for both Puma and p21. Importantly, one patient without known 11q-or 17p-was p53 dysfunctional according to RT-MLPA and WB analysis (patient 2; Table 1 ). This case, as well as patient 28 underscore the occasional, but clinically highly relevant divergence between determination of p53 status by functional testing and by FISH analysis.
By applying threshold values for Puma, p21 and Bax as detected by RT-MLPA, p53 dysfunction could reliably be detected in this cohort of CLL patients, and was concordant among distinct methods. CD95 FACS analysis, which yielded an unrealistic cut-off value of 0.8 for increase in MFI owing to a larger SD, did not allow to discriminate p53 dysfunction, (see Table 1 ). In Figure 1d , average fold induction for Puma, p21, Bax and CD95 is plotted for all samples assigned normal or dysfunctional p53 status, which yielded highly significant differences for Puma, p21 and Bax.
Lastly, an attempt was made to approximate cut-off values for p53 dysfunction in heterogenous samples. RNA from established p53 dysfunctional cells (Ramos Burkitt's lymphoma) was incrementally mixed with RNA from p53 WT CLL. A conservative estimate based on expression of Puma (Figure 1e ) suggested that B50% p53 dysfunctional cells in a sample will allow discrimination, which agrees well with the analysis shown in Figure 1c . Clearly, this important parameter should be more accurately established in a larger cohort, in relation with FISH criteria, as it is known that 17p-status in the 10-50% range also has a negative clinical impact.
Taken together, these data indicate that RT-MLPA is a useful tool to detect p53 dysfunction in CLL and other malignant cells, in particular, when this is not caused by deletion of the TP53 gene. The RT-MLPA method is well suited for standardisation Table 1 . P-values calculated by 2-sided paired Student's t-test for differences between the two groups are indicated. (e) RT-MLPA response for Puma in heterogeneous samples. RNA obtained from 2 p53 functional CLL samples and p53 dysfunctional Ramos Burkitt's lymphoma cells after IR was mixed in various ratios as indicated. There were significant differences between CLL and Ramos in (basal) Puma expression, which precluded calculation of fold induction values in the mixed RNA. Therefore, relative expression levels for Puma were averaged and plotted instead. by defining robust cut-off values in a larger, well-defined (international) reference cohort. Such future studies may also allow determination of clinically relevant thresholds in heterogenous samples. Other advantages are the potential for automation and the relatively low costs. We conclude that this type of functional read-out for p53 could be a valuable contribution to diagnostic and therapeutic criteria, and should be further tested in the prospective clinical trials.
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Immunoglobulin and T-cell receptor gene rearrangements as PCR-based targets are stable markers for monitoring minimal residual disease in acute lymphoblastic leukemia after stem cell transplantation Alterations of phenotypic or genotypic markers because of clonal development or selection between disease episodes interfere with the detection of minimal residual disease (MRD) in acute leukemia. This issue has been investigated extensively for relapses after induction and reinduction therapy in acute lymphoblastic leukemia (ALL), in which the usage of rearranged immunogenes is well established (Szczepanski et al. 1 and Guggemos et al., 2 and references therein). Currently, allogeneic hematopoietic stem cell transplantation (SCT) is the only curative treatment for many high-risk patients with ALL, but relapse is still the most frequent reason for treatment failure. MRD studies after SCT have shown significant associations between MRD positivity and relapse, [3] [4] [5] [6] and, therefore, these studies could form the basis for further interventional preemptive immunotherapy strategies to prevent relapse. With regard to marker stability, however, these studies either did not compare junctional region sequences or limited their investigations to particular gene loci.
Detailed sequencing analysis of immunoglobulin and T-cell receptor (Ig/TCR) rearrangements is the most reliable way to understand how rearrangements persist or evolve during the course of the disease. To assess the extent of marker changes after allogeneic SCT, we performed a retrospective analysis by characterizing currently used IgH, IgK-deletion (IgK-Kde), TCR-g, TCR-d and TCR-b gene rearrangements with BIOMED-1 and BIOMED-2 primers 7, 8 for target identification and subsequent sequence analyses according to the European Study group on MRD detection in ALL (ESG-MRD-ALL). 9 We compared leukemia blast samples from the initial or relapse diagnosis with samples from a subsequent relapse after allogeneic SCT. The cases included 40 pediatric and adolescent ALL patients who suffered a relapse after undergoing allogeneic SCT in the first (CR1, n ¼ 8) and either the second (CR2, n ¼ 25) or the third (CR3, n ¼ 7) complete remissions between 1997 and 2006. Of these patients, 38 were diagnosed for precursor B-ALL and 2 for T-ALL. All patients were pretreated according to the protocols ALL-BFM (n ¼ 7), ALL-REZ-BFM (n ¼ 32) of the Berlin-Frankfurt-Münster Group and CoALL (n ¼ 1) of the German Cooperative Study Group for Childhood ALL. The median age at transplantation was 10.2 years, ranging from 1.5 to 22.2 years. Relapse occurred between 54 and 1188 days (3.3 years) after transplantation (median: 0.61 years), without significant differences between patients transplanted in the CR1 (median 0.47 years), CR2
